Literature DB >> 21863061

Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma.

Ulrike Maegdefrau1, Stephanie Arndt, Georgi Kivorski, Claus Hellerbrand, Anja-Katrin Bosserhoff.   

Abstract

Recently, we revealed that bone morphogenetic protein (BMP) 4 is increased in hepatocellular carcinoma (HCC). Furthermore, latest reports described BMPs, in particular BMP6, as important regulators of hepcidin expression in iron homeostasis. Therefore, we aimed to unravel why enhanced BMP expression in HCC patients does not lead to severe changes in iron metabolism. Initial analysis of the BMP4 and BMP6 expression patterns revealed enhanced expression on mRNA and protein level in HCC cell lines and tissue samples compared with primary human hepatocytes (PHHs) and normal liver tissues. However and interestingly, hepcidin expression was reduced in HCC cell lines and tissues. Analysis of BMP6 receptor expression revealed loss of BMP6-specific receptor subunit in HCC. To identify a possible regulatory mechanism causing lack of reaction to BMP4 we analyzed the expression of hemojuvelin (HJV), which is involved in iron metabolism as BMP co-receptor. HJV expression was markedly decreased in HCC cell lines and tissues. HJV promoter analysis revealed potential HNF-1α and snail-binding sites, but functional analysis ruled out that these transcriptional regulators or promoter methylation are the cause of HJV downregulation in HCC. However, we identified AU-rich elements in the HJV 3'-untranslated region and revealed significantly faster decay of HJV mRNA in HCC cells as compared with PHH indicating decreased mRNA-stability as the reason for the loss of HJV expression in HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21863061     DOI: 10.1038/labinvest.2011.123

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling.

Authors:  Katarzyna Mleczko-Sanecka; Franziska Roche; Ana Rita da Silva; Debora Call; Flavia D'Alessio; Anan Ragab; Philip E Lapinski; Ramesh Ummanni; Ulrike Korf; Christopher Oakes; Georg Damm; Lorenza A D'Alessandro; Ursula Klingmüller; Philip D King; Michael Boutros; Matthias W Hentze; Martina U Muckenthaler
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

2.  Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Xiaodong Guo; Lu Xiong; Lin Zou; Jingmin Zhao
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

3.  Hemojuvelin deficiency promotes liver mitochondrial dysfunction and predisposes mice to hepatocellular carcinoma.

Authors:  Abdolamir Allameh; Nico Hüttmann; Edouard Charlebois; Angeliki Katsarou; Wen Gu; Konstantinos Gkouvatsos; Elisa Pasini; Mamatha Bhat; Zoran Minic; Maxim Berezovski; Maria Guido; Carine Fillebeen; Kostas Pantopoulos
Journal:  Commun Biol       Date:  2022-02-22

Review 4.  Hepcidin in hepatocellular carcinoma.

Authors:  Jonathan H Joachim; Kosha J Mehta
Journal:  Br J Cancer       Date:  2022-03-09       Impact factor: 9.075

Review 5.  TGF-β superfamily co-receptors in cancer.

Authors:  John B Pawlak; Gerard C Blobe
Journal:  Dev Dyn       Date:  2021-04-09       Impact factor: 3.780

6.  BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.

Authors:  Blanca Herrera; María García-Álvaro; Silvia Cruz; Peter Walsh; Margarita Fernández; Cesáreo Roncero; Isabel Fabregat; Aránzazu Sánchez; Gareth J Inman
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

7.  Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma.

Authors:  Yinghua He; Ying Cui; Baiying Xu; Jun Gu; Wei Wang; Xiaoying Luo
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 8.  BMP signaling and its paradoxical effects in tumorigenesis and dissemination.

Authors:  Lijie Zhang; Yingnan Ye; Xinxin Long; Pei Xiao; Xiubao Ren; Jinpu Yu
Journal:  Oncotarget       Date:  2016-11-22

Review 9.  Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.

Authors:  Driton Vela; Zana Vela-Gaxha
Journal:  Exp Mol Med       Date:  2018-02-02       Impact factor: 8.718

10.  HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway.

Authors:  Ying Shen; Xin Li; Yanwei Su; Shaikh Atik Badshah; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Diagnostics (Basel)       Date:  2019-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.